NCT04432714 - Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions

DLBCLUntreatedMYC Gene Rearrangement

Interventions

DRUG

Lenalidomide

Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle

DRUG

Rituximab

Rituximab 375 mg/m2，IV, d0

DRUG

Etoposide

Etoposide 50 mg/m2/day CI24h d1-d4

DRUG

Doxorubicin

Doxorubicin 10 mg/m2/day CI24h d1-d4

DRUG

Vincristine

Vincristine 0.4mg/m2/day CI24h d1-d4

DRUG

Cyclophosphamide

Cyclophosphamide 750 mg/m2/day IV d5

DRUG

Prednisone

Prednisone 60 mg/m2/bid oral or IV d1-d5

Trial Locations (1)

RECRUITING

The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER